Progenika Inc

PROGENIKA’s BLOOD GROUP GENOTYPING TEST AVAILABLE THROUGH ARUP LABORATORIES

Cambridge, MA, October 22, 2009 – Progenika, Inc. today announced that it has entered into an agreement with ARUP Laboratories (ARUP) of Salt Lake City, UT, to provide blood group genotyping reference laboratory services to ARUP to determine patient red blood cell antigen profiles when serology has logistic and functional limitations. Progenika’s blood group genotyping microarray, which simultaneously detects over 100 genetic variants in the nine blood group systems that are most relevant to transfusion safety, overcomes these serological limitations.

Read more...
 
  1. home
  2. About Progenika
  3. Progenika Group

Progenika Group

Progenika

www.progenika.com

Progenika Biopharma, S.A.

Progenika Biopharma S.A. is a privately owned Spanish company founded in April 2000, with the aim of designing and developing tools for Personalized Medicine.

The company develops and manufactures novel DNAchips for genotyping that can be used in the diagnosis and prognosis of human diseases.

More than 60 scientists work at Progenika, whose state-of-the-art facilities are situated in the Bizkaia Technology Park in the outskirts of Bilbao (Spain). Progenika’s fully equipped installations are specifically designed for the production and analysis of DNAchips. This cutting-edge equipment is backed up by a team of computer experts who develop the algorithms and software that facilitate the automatic interpretation of DNAchip results.

Proteomika

www.proteomika.com

Proteomika, S.L.

A subsidiary company of Progenika Biopharma S.A., Proteomika S.L. specializes in protein biomarker detection. Proteomics technologies are used to search for diagnostic, prognostic and drug response biomarkers in urine, serum, lung wash or endometrial fluid samples.

Those biomarkers are later converted into a kit to diagnose, prognose, predict or monitor drug response of Human Diseases.  These kits are known as ProteinChip, Bead-based array or ELISA kit.

Abyntek

www.abyntek.com

Abyntek Biopharma S.L.

Abyntek Biopharma S.L. is a privately owned biotechnology company that centers its activity in developing, producing and commercializing antigens and antibodies.

A strong investment in R&D constitutes one of the fundamental values on which the business strategy of Abyntek is based. The R&D activities of Abyntek focus on two main areas:

  • The development of new technologies to produce monoclonal antibodies.
  • The development of diagnostic and prognostic products, as well as products to predict the response to treatment and for the treatment of lung diseases.